Format
Sort by
Items per page

Send to

Choose Destination

Best matches for hemodialysis AND ("QT" OR Torsad*):

Search results

Items: 1 to 20 of 198

1.

Prevalence and risk factors of acquired long QT syndrome in hospitalized patients with chronic kidney disease.

Liu P, Han D, Sun X, Tan H, Wang Z, Liu C, Zhang Y, Li B, Sun C, Shi R, Li G.

J Investig Med. 2018 Oct 26. pii: jim-2018-000798. doi: 10.1136/jim-2018-000798. [Epub ahead of print]

PMID:
30367011
2.

Effect of Hemodialysis on Corrected QT Interval and QTc Dispersion.

Sohal PM, Goel A, Gupta D, Aslam N, Sandhu J, Sandhu JS, John EE, Sharma D.

Indian J Nephrol. 2018 Sep-Oct;28(5):335-338. doi: 10.4103/ijn.IJN_15_18.

3.

TpTe and TpTe/QT: novel markers to predict sudden cardiac death in ESRD?

Saour BM, Wang JH, Lavelle MP, Mathew RO, Sidhu MS, Boden WE, Sacco JD, Costanzo EJ, Hossain MA, Vachharanji T, Alrefaee A, Asif A.

J Bras Nefrol. 2018 Aug 16. pii: S0101-28002018005026101. doi: 10.1590/2175-8239-JBN-2017-0021. [Epub ahead of print] English, Portuguese.

4.

Current Perspectives on Sudden Cardiac Death in Hemodialysis Patients.

Joki N, Tokumoto M, Takahashi N, Nishimura M.

Contrib Nephrol. 2018;196:5-12. doi: 10.1159/000485690. Epub 2018 Jul 24.

PMID:
30041198
5.

Role of genetic and electrolyte abnormalities in prolonged QTc interval and sudden cardiac death in end-stage renal disease patients.

Coll M, Ferrer-Costa C, Pich S, Allegue C, Rodrigo E, Fernández-Fresnedo G, Barreda P, Mates J, Martinez de Francisco AL, Ortega I, Iglesias A, Campuzano O, Salas E, Arias M, Brugada R.

PLoS One. 2018 Jul 18;13(7):e0200756. doi: 10.1371/journal.pone.0200756. eCollection 2018.

6.

Treatment of extreme hypercalcaemia: the role of haemodialysis.

Basok AB, Rogachev B, Haviv YS, Vorobiov M.

BMJ Case Rep. 2018 Jun 4;2018. pii: bcr-2017-223772. doi: 10.1136/bcr-2017-223772.

7.

Can hemodialysis change QRS axis in patients without cardiovascular disease?

Korkmaz A, Yıldız A, Kundi H, Başyigit F, Gürsoy HT, Uçar Elalmış Ö, Akyüz A, İleri M, Güray Ü.

Turk Kardiyol Dern Ars. 2018 Jun;46(4):276-282. doi: 10.5543/tkda.2018.37666.

8.

Theoretical overview of clinical and pharmacological aspects of the use of etelcalcetide in diabetic patients undergoing hemodialysis.

Ye J, Deng G, Gao F.

Drug Des Devel Ther. 2018 Apr 19;12:901-909. doi: 10.2147/DDDT.S160223. eCollection 2018. Review.

9.

Managing hyperparathyroidism in hemodialysis: role of etelcalcetide.

Eidman KE, Wetmore JB.

Int J Nephrol Renovasc Dis. 2018 Feb 5;11:69-80. doi: 10.2147/IJNRD.S128252. eCollection 2018. Review.

10.

TANGO2-Related Metabolic Encephalopathy and Arrhythmias.

Lalani SR, Graham B, Burrage L, Lai YC, Scaglia F, Miyake C, Yang Y.

In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2018.
2018 Jan 25.

11.

Effects of L- and N-Type Ca Channel Blocker Cilnidipine on Changes in Heart Rate and QT Interval During Dialysis.

Iida T, Morimoto S, Amari Y, Ando T, Ichihara A.

Kidney Blood Press Res. 2017;42(5):933-941. doi: 10.1159/000485083. Epub 2017 Nov 22.

12.

Association of QT-Prolonging Medication Use in CKD with Electrocardiographic Manifestations.

Snitker S, Doerfler RM, Soliman EZ, Deo R, St Peter WL, Kramlik S, Fischer MJ, Navaneethan S, Delafontaine P, Jaar BG, Ojo A, Makos GK, Slaven A, Weir MR, Zhan M, Fink JC; for CRIC Study Investigators.

Clin J Am Soc Nephrol. 2017 Aug 9;12(9). pii: CJN.12991216. doi: 10.2215/CJN.12991216. Print 2017 Sep 7.

13.

Reproducibility and Reliability Of QTc and QTcd Measurements and Their Relationships with Left Ventricular Hypertrophy in Hemodialysis Patients.

Alonso MAG, Lima VACC, Carreira MAMQ, Lugon JR.

Arq Bras Cardiol. 2017 Sep;109(3):222-230. doi: 10.5935/abc.20170112. Epub 2017 Aug 7. English, Portuguese.

14.

Relationship Between Angiotensin-converting Enzyme Gene Polymorphism and QT Dispersion in Hemodialysis Patients.

Toraman A, Colak H, Tekce H, Cam S, Kursat S.

Iran J Kidney Dis. 2017 May;11(3):217-222.

15.

Are Markers of Cardiac Dysfunction Useful in the Assessment of Cardiovascular Risk in Dialysis Patients?

Franczyk B, Gluba-Brzózka A, Bartnicki P, Banach M, Rysz J.

Curr Pharm Des. 2017;23(20):3024-3033. doi: 10.2174/1381612823666170508152501.

PMID:
28486916
16.

Noninvasive quantification of blood potassium concentration from ECG in hemodialysis patients.

Corsi C, Cortesi M, Callisesi G, De Bie J, Napolitano C, Santoro A, Mortara D, Severi S.

Sci Rep. 2017 Feb 15;7:42492. doi: 10.1038/srep42492.

17.

Hemodialysis-induced repolarization abnormalities on ECG are influenced by serum calcium levels and ultrafiltration volumes.

Ozportakal H, Ozkok A, Alkan O, Bulut AS, Boyraz M, Inanir M, Acar G, Odabas AR.

Int Urol Nephrol. 2017 Mar;49(3):509-515. doi: 10.1007/s11255-016-1472-z. Epub 2016 Dec 10.

PMID:
27943168
18.

Assessment of drug-induced proarrhythmias due to pilsicainide in patients with atrial tachyarrhythmias.

Koike H, Fujino T, Koike M, Yao S, Shinohara M, Kitahara K, Kinoshita T, Yuzawa H, Suzuki T, Sato H, Fukunaga S, Kobayashi K, Ikeda T.

J Arrhythm. 2016 Dec;32(6):468-473. Epub 2016 May 26.

19.

Propionic Acidemia.

Shchelochkov OA, Carrillo N, Venditti C.

In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2018.
2012 May 17 [updated 2016 Oct 6].

20.

The effects of different electrolyte composition in dialysate on QTc interval; a controlled trial.

Sabzghabaei F, Heydariezade SA, Joodat RS.

J Renal Inj Prev. 2016 Apr 6;5(3):153-6. doi: 10.15171/jrip.2016.32. eCollection 2016.

Supplemental Content

Loading ...
Support Center